

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders
ID1319

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche pharmaceuticals (satralizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain and Spine Foundation • Contact a Family • Eyecare Trust • Fight for Sight • Leonard Cheshire Disability • Muslim Council of Britain • National Federation of the Blind UK • Neurological Alliance • NMO Spectrum UK • OBAC • Royal National Institute of Blind People • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • The Brain Charity • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Optometrists • British Geriatrics Society • British Neuropathological Society • British Ophthalmic Anaesthesia Society • College of Optometrists • Institute of Neurology • Optical Confederation • Oxford Eye Foundation • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Council for the Blind • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (azathioprine, methotrexate, prednisolone) • Advanz pharma (methotrexate, prednisolone) • Alexion (eculizumab) • Allergan UK (prednisolone) • Alliance pharmaceuticals (prednisolone) • Aspen (azathioprine) • Bausch and Lomb (prednisolone) • Cipla EU (methotrexate)

Provisional stakeholder list for the proposed single technology appraisal of satralizumab for preventing relapses in neuromyelitis optica spectrum disorders ID1319

Issue date: September 2019

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Great Yarmouth & Waveney CCG • NHS North Derbyshire CCG • Welsh Government 	<ul style="list-style-type: none"> • Ennogen pharma (azathioprine) • Hospira UK (methotrexate) • Logixx pharma (prednisolone) • Medac (methotrexate) • Mylan (azathioprine) • Nordic pharma (methotrexate) • Orion pharma (methotrexate) • Pfizer (methotrexate) • Rosemont pharmaceuticals (methotrexate) • Sandoz (methotrexate) • Therakind (methotrexate) • Viela Bio (inebilizumab) • Wockhardt UK (prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Cochrane Eyes and Vision Group • Eye Hope • Genomics England • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.